← Back to Search

Other

CY6463 for Alzheimer's Disease

Phase 2
Waitlist Available
Research Sponsored by Cyclerion Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose of study treatment through ~14 (±4) days after the final dose
Awards & highlights

Study Summary

This study is evaluating whether a drug called CY6463 is safe and tolerable for people with Alzheimer's disease.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose of study treatment through ~14 (±4) days after the final dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose of study treatment through ~14 (±4) days after the final dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment-emergent adverse events (TEAEs) from study drug initiation through Follow-up

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CY6463Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CY6463
2021
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Cyclerion TherapeuticsLead Sponsor
17 Previous Clinical Trials
885 Total Patients Enrolled
Tisento TherapeuticsLead Sponsor
4 Previous Clinical Trials
190 Total Patients Enrolled
Chad Glassar, PharmDStudy DirectorCyclerion Therapeutics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
2021. "A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04798989.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top